# A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o

Source: https://onco.cc/trials/nct06155396/  
OnCo record `nct06155396` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Disitamab vedotin, Zimberelimab in cervical cancer, run by RemeGen Co., Ltd., now recruiting.

## Summary

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06155396 by RemeGen Co., Ltd., with 116 participants planned, started 2024-01-11 and due to reach its primary completion in 2027-06-30. Interventions recorded: Disitamab Vedotin, Zimberelimab. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06155396
- Phase: 2
- Setting: A Single-Arm, Open- Label, Multicenter Phase II Study of RC48-ADC in Combination With Zimberelimab Injection for the Treatment ,at Least First-line Platinum-containing Standard Therapy Failed in HER2-expressing Subject With Recurrent or Metastatic Cervical Cancer
- Sponsor: RemeGen Co., Ltd.
- Enrolled: 116

## Sources

- ClinicalTrials.gov NCT06155396: https://clinicaltrials.gov/study/NCT06155396

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)

---
JSON: https://onco.cc/api/v1/entities/nct06155396.json